Promote Your Research… Share it Worldwide
Have a story or a research paper to share? Become a contributor and publish your work on AcademicJobs.com.
Submit your Research - Make it Global NewsBreakthrough from Imperial College London Researchers
Researchers at Imperial College London have unveiled promising results from a phase IIa clinical trial exploring the potential of dimethyltryptamine (DMT), the primary psychoactive compound in ayahuasca, as a treatment for major depressive disorder (MDD). Led by Dr. David Erritzoe from the Department of Brain Sciences, the study demonstrates that a single intravenous dose of DMT, administered with psychotherapeutic support, led to significant and sustained reductions in depressive symptoms among participants with treatment-resistant depression. This development underscores the growing role of UK universities in pioneering psychedelic-assisted therapies for mental health challenges.
The trial, published in Nature Medicine on February 16, 2026, involved 34 adults with moderate-to-severe MDD who had not responded to at least two prior treatments, such as antidepressants or psychotherapy. Participants were randomized to receive either DMT or a placebo, marking a key advancement in short-acting psychedelic interventions.
Understanding Ayahuasca and DMT: From Traditional Brew to Clinical Compound
Ayahuasca, a traditional Amazonian brew used in indigenous shamanic rituals for centuries, contains N,N-dimethyltryptamine (DMT), a potent serotonergic psychedelic that induces profound altered states of consciousness. In its natural form, ayahuasca is typically ingested orally, with monoamine oxidase inhibitors (MAOIs) from plants like Banisteriopsis caapi enabling DMT to cross the blood-brain barrier and produce effects lasting 4-6 hours. However, the clinical trial utilized a synthetic, pharmaceutical-grade intravenous formulation of DMT fumarate (SPL026), which bypasses the need for oral MAOIs and results in a brief 20-30 minute psychedelic experience.
This step-by-step process highlights DMT's unique pharmacokinetics: after IV infusion over 10 minutes, it rapidly peaks in the brain, triggering serotonin 5-HT2A receptor activation, which is believed to promote neuroplasticity, emotional processing, and a 'reset' of default mode network activity associated with rumination in depression. Unlike longer-acting psychedelics like psilocybin (from magic mushrooms), DMT's short duration could make it more practical for clinical settings, potentially lowering costs and logistical burdens for therapists and patients.
Study Design: Rigorous Methodology in a UK-Led Trial
Conducted across sites in London and Liverpool, the double-blind, placebo-controlled trial followed standard phase IIa protocols to assess dosing, safety, and preliminary efficacy. Participants underwent pre-dose preparation sessions, including psychological screening and therapeutic rapport-building, followed by a 21.5 mg DMT infusion or placebo. During the session, supportive psychotherapy was provided, with integration sessions afterward to help process insights.
The primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores at two weeks post-dose, a validated clinician-rated measure ranging from 0-60, where scores above 30 indicate severe depression. Secondary outcomes included response rates (≥50% MADRS reduction) and remission (MADRS ≤10). An open-label extension allowed placebo recipients to receive DMT, enabling comparisons of single vs. repeated dosing.
This design reflects best practices in psychedelic research, emphasizing set (mindset), setting (environment), and therapeutic support—elements central to Imperial College's Centre for Psychedelic Research, the world's first dedicated to brain imaging and clinical applications of these compounds.
Key Results: Rapid and Sustained Antidepressant Effects
The DMT group exhibited markedly superior outcomes. At one week, MADRS scores dropped by an average of 15.4 points in the DMT arm versus 4.6 in placebo (mean difference -10.8 points; P=0.002; Cohen's d=1.09). By two weeks, the difference was -7.35 points (P=0.023; d=0.82). Response rates reached 35% (DMT) vs. 12% (placebo), with 29% remission in DMT vs. 12%.
- Effects onset within hours, peaking at one week.
- Sustained to three months in open-label phase, with 40% response and 44% remission at six months overall.
- Benefits correlated with mystical experience intensity, measured by validated scales.
No advantage for a second dose, suggesting single administration may suffice. These findings rival longer psilocybin trials from Imperial, where effects lasted months after 6-8 hour sessions.
Read the full Nature Medicine paperSafety Profile: Well-Tolerated with Minimal Risks
DMT was safe across the cohort, with 73.5% experiencing mild-moderate treatment-emergent adverse events (TEAEs) like infusion-site pain (38%), nausea (18%), and transient anxiety (18%), all resolving quickly. No serious adverse events, suicidal ideation changes, or vital sign abnormalities occurred. This profile aligns with prior DMT safety data, with transient blood pressure/heart rate increases typical of serotonergics.
Exclusion of high-suicide-risk individuals and therapeutic oversight mitigated potential 'bad trips.' UK experts note DMT's brevity reduces prolonged distress risks compared to ayahuasca ceremonies, where vomiting and 4+ hour durations are common.
Expert Perspectives from UK Academics
Dr. Liliana Galindo (University of Cambridge) hailed it as a "welcome glimmer of hope," praising rapid onset and tolerability, positioning DMT as time-efficient. Prof. James Stone (Brighton and Sussex Medical School) called it an "exciting proof-of-concept," aligning with psilocybin's reintegration benefits but cautioning on small N=34 and blinding challenges due to unmistakable effects.
Dr. James Rucker (King's College London) views it as additive evidence for psychedelics in supportive settings, though expectancy effects confound interpretation. Prof. Ian Maidment (Aston University) stresses phase III needs for definitive efficacy, noting 88% white participants limit generalizability.
Dr. Erritzoe emphasized: "A single DMT experience of just around 25 minutes... holds great promise... likely more cost-effective."
Psychedelic Research Boom at UK Universities
Imperial's Centre for Psychedelic Research, launched in 2019, leads with fMRI studies on LSD/psilocybin brain effects and depression trials (e.g., psilocybin vs. escitalopram). King's College London's Psychoactive Trials Group partners with COMPASS Pathways on phase 3 psilocybin for TRD, the largest such program. UCL trials psychedelics for alcohol use. Funded by philanthropists and pharma like Cybin, these efforts position UK academia at the forefront amid global resurgence.Explore research jobs in UK psychedelics
The UK Depression Crisis: Why New Treatments Matter
Depression affects 1 in 6 UK adults, with NHS waiting lists exceeding 1.8 million for mental health services. Treatment-resistant depression (TRD) impacts 15-30% (up to 48% per recent analyses), where two+ antidepressants fail, costing £9.5bn yearly in lost productivity. Current options like SSRIs remit only 30%, leaving many in limbo. University-led innovations like DMT could alleviate NHS burdens, especially post-COVID surge.
Challenges and Limitations in Psychedelic Trials
Small sample, lack of diversity (88% white), and blinding infeasibility (psychedelic effects obvious) risk expectancy bias. Exclusion of severe suicide cases limits scope. Regulatory hurdles persist: DMT is Schedule 1 (Class A), restricting access outside trials despite MHRA approvals for studies. Ethical integration therapy training is vital.
Future Directions: Larger Trials and NHS Integration
Phase III trials are next, with Cybin/Helus planning expansions. Potential for NHS psychedelic clinics, akin to ketamine services. UK policy (POSTnote 2023) urges frameworks for PAT. Imperial aims for diverse cohorts, comparing DMT to gold standards.Guardian coverage
Opportunities abound for postdoc positions in psychopharmacology.
Photo by Jonas Stolle on Unsplash
Implications for UK Higher Education and Mental Health Careers
This study exemplifies interdisciplinary collaboration: neuroscience, psychiatry, psychotherapy at Imperial. Rising demand for psychedelic researchers boosts lecturer jobs in brain sciences. For students, explore psychopharmacology via university programs.
In conclusion, Imperial's DMT trial heralds a paradigm shift. Aspiring academics, check Rate My Professor for insights, browse higher ed jobs, and career advice. University jobs in mental health research are expanding—post a job today.
Be the first to comment on this article!
Please keep comments respectful and on-topic.